HTR2A: Association and expression studies in neuropsychiatric genetics

Annals of Medicine

Volumn 37, Issue 2, 2005, Pages 121-129

  Norton, Nadine ^a   Owen, Michael J ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

5 hydroxytryptamine (serotonin) receptor 2A; 5HT2A; Association; HTR2A; Neuropsychiatric; Serotonin 5 HT 2 receptor

Indexed keywords

DOPAMINE TRANSPORTER; SEROTONIN 2A RECEPTOR;

ALLELE; ALZHEIMER DISEASE; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BEHAVIOR GENETICS; CLINICAL TRIAL; EATING DISORDER; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC CORRELATION; HUMAN; KNOCKOUT MOUSE; META ANALYSIS; MOOD DISORDER; NERVE CONDUCTION; NEUROPSYCHIATRY; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; REVIEW; SCHIZOPHRENIA; SUICIDE;

ALZHEIMER DISEASE; ANIMALS; ANXIETY DISORDERS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CLINICAL TRIALS; EATING DISORDERS; HUMANS; MENTAL DISORDERS; MOOD DISORDERS; RECEPTOR, SEROTONIN, 5-HT2A; SCHIZOPHRENIA; SEROTONIN; SUICIDE;

EID: 17844377615     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.1080/07853890510037347     Document Type: Review

References (103)

1. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev. 1994;46:157-203.
2. Azmitia EC. Modern views on an ancient chemical: serotonin effects on cell proliferation, maturation, and apoptosis. Brain Res Bull. 2001;56:413-24.
3. Lucki I. The spectrum of behaviors influenced by serotonin. Biol Psychiatry. 1998;44:151-62.
4. Gingrich JA, Ansorge MS, Merker R, Weisstaub N, Zhou M. New lessons from knockout mice: The role of serotonin during development and its possible contribution to the origins of neuropsychiatric disorders. CNS Spectr. 2003; 8:572-7.
5. Muller-Oerlinghausen B, Roggenbach J, Franke L. Serotonergic platelet markers of suicidal behavior - do they really exist? J Affect Disord. 2004;79:13-24.
6. Harvey L, Reid RE, Ma C, Knight PJ, Pfeifer TA, Grigliatti TA. Human genetic variations in the 5HT2A receptor: a single nucleotide polymorphism identified with altered response to clozapine. Pharmacogenetics. 2003;13: 107-18.
7. Warren JT, Jr. Peacock ML, Rodriguez LC, Fink JK. An MspI polymorphism in the hyman serotonin receptor gene (HTR2): detection by DGGE and RFLP analysis. Hum Mol Genet. 1993;2:338.
8. Inayama Y, Yoneda H, Sakai T, Ishida T, Nonomura Y, Kono Y, et al. Positive association between a DNA sequence variant in the serotonin 2A receptor gene and schizophrenia. Am J Med Genet. 1996;67:103-5.
9. O'Donovan MC, Owen MJ. Basic molecular genetics. In: McGuffin P, Owen MJ, Gottesman II, editors. Psychiatric Genetics and Genomics. Oxford: Oxford University Press, 2002: p. 3-29.
10. Spurlock G, Heils A, Holmans P, Williams J, D'Souza UM, Cardno A, et al. A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter. Mol Psychiatry. 1998;3:42-9.
11. Parsons MJ, D'Souza UM, Arranz MJ, Kerwin RW, Makoff AJ. The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biol Psychiatry. 2004;56:406-10.
12. Turecki G, Briere R, Dewar K, Antonetti T, Lesage AD, Seguin M, et al. Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide. Am J Psychiatry. 1999;156:1456-8.
13. Kouzmenko AP, Hayes WL, Pereira AM, Dean B, Burnet PW, Harrison PJ. 5-HT2A receptor polymorphism and steady state receptor expression in schizophrenia. Lancet. 1997;349:1815.
14. Kouzmenko AP, Scaffidi A, Pereira AM, Hayes WL, Copolov DL, Dean B. No correlation between A(-1438)G polymorphism in 5-HT2A receptor gene promoter and the density of frontal cortical 5-HT2A receptors in schizophrenia. Hum Hered. 1999;49:103-5.
15. Polesskaya OO, Sokolov BP. Differential expression of the "C" and "T" alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J Neurosci Res. 2002;67:812-22.
16. Bray NJ, Buckland PR, Hall H, Owen MJ, O'Donovan MC. The serotonin-2A receptor gene locus does not contain common polymorphism affecting mRNA levels in adult brain. Mol Psychiatry. 2004;9:109-14.
17. Growdon WB, Cheung BS, Hyman BT, Rebeck GW. Lack of allelic imbalance in APOE epsilon3/4 brain mRNA expression in Alzheimer's disease. Neurosci Lett. 1999;272:83-6.
18. Norton N, Williams NM, Williams HJ, Spurlock G, Kirov G, Morris DW, et al. Universal, robust, highly quantitative SNP allele frequency measurement in DNA pools. Hum Genet. 2002;110:471-8.
19. Arranz M, Collier D, Sodhi M, Ball D, Roberts G, Price J, et al. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet. 1995;346: 281-2.
20. Arranz MJ, Collier DA, Munro J, Sham P, Kirov G, Sodhi M, et al. Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neurosci Lett. 1996;217:177-8.
21. Arranz MJ, Munro J, Sham P, Kirov G, Murray RM, Collier DA, et al. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res. 1998;32:93-9.
22. Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 1999;21:106-15.
23. Williams J, Spurlock G, McGuffin P, Mallet J, Nothen MM, Gill M, et al. Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group. Lancet. 1996; 347:1294-6.
24. Williams J, McGuffin P, Nothen M, Owen MJ. Meta-analysis of association between the 5-HT2a receptor T102C polymorphism and schizophrenia. EMASS Collaborative Group. European Multicentre Association Study of Schizophrenia. Lancet. 1997;349:1221.
25. Arranz MJ, Lin MW, Powell J, Kerwin R, Collier D. 5HT 2a receptor T102C polymorphism and schizophrenia. Lancet. 1996;347:1831-2.
26. Jonsson E, Nothen MM, Bunzel R, Propping P, Sedvall G. 5HT 2a receptor T102C polymorphism and schizophrenia. Lancet. 1996;347:1831.
27. Malhotra AK, Goldman D, Buchanan R, Breier A, Pickar D. 5HT 2a receptor T102C polymorphism and schizophrenia. Lancet. 1996;347:1830-1.
28. Nimgaonkar VL, Zhang XR, Brar JS, DeLeo M, Ganguli R. 5-HT2 receptor gene locus: association with schizophrenia or treatment response not detected. Psychiatr Genet. 1996;6:23-7.
29. Sasaki T, Hattori M, Fukuda R, Kunugi H, Nanko S. 5HT 2a receptor T102C polymorphism and schizophrenia. Lancet. 1996;347:1832.
30. Hawi Z, Myakishev MV, Straub RE, O'Neill A, Kendler KS, Walsh D, et al. No association or linkage between the 5-HT2a/T102C polymorphism and schizophrenia in Irish families. Am J Med Genet. 1997;74:370-3.
31. Shinkai T, Ohmori O, Kojima H, Terao T, Suzuki T, Abe K. Negative association between T102C polymorphism of the 5-HT2a receptor gene and schizophrenia in Japan. Hum Hered. 1998;48:212-5.
32. Chen RY, Sham P, Chen EY, Li T, Cheung EF, Hui TC, et al. No association between T102C polymorphism of serotonin-2A receptor gene and clinical phenotypes of Chinese schizophrenic patients. Psychiatry Res. 2001;105:175-85.
33. Abdolmaleky HM, Faraone SV, Glatt SJ, Tsuang MT. Meta-analysis of association between the T102C polymorphism of the 5HT2a receptor gene and schizophrenia. Schizophr Res. 2004;67:53-62.
34. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet. 2003;33:177-82.
35. Dean B, Hayes W. Decreased frontal cortical serotonin2A receptors in schizophrenia. Schizophr Res. 1996;21:133-9.
36. Laruelle M, Abi-Dargham A, Casanova MF, Toti R, Weinberger DR, Kleinman JE. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. Arch Gen Psychiatry. 1993;50:810-8.
37. Lopez-Figueroa AL, Norton CS, Lopez-Figueroa MO, Armellini-Dodel D, Burke S, Akil H, et al. Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia. Biol Psychiatry. 2004;55:225-33.
38. Eastwood SL, Burnet PW, Gittins R, Baker K, Harrison PJ. Expression of serotonin 5-HT(2A) receptors in the human cerebellum and alterations in schizophrenia. Synapse. 2001;42:104-14.
39. Hernandez I, Sokolov BP. Abnormalities in 5-HT2A receptor mRNA expression in frontal cortex of chronic elderly schizophrenics with varying histories of neuroleptic treatment. J Neurosci Res. 2000;59:218-25.
40. Burnet PW, Eastwood SL, Harrison PJ. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology. 1996;15:442-55.
41. Anguelova M, Benkelfat C, Turecki G. A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: I. Affective disorders. Mol Psychiatry. 2003;8:574-91.
42. Ranade SS, Mansour H, Wood J, Chowdari KV, Brar LK, Kupfer DJ, et al. Linkage and association between serotonin 2A receptor gene polymorphisms and bipolar I disorder. Am J Med Genet. 2003;121B:28-34.
43. Choi MJ, Lee HJ, Lee HJ, Ham BJ, Cha JH, Ryu SH, et al. Association between major depressive disorder and the -1438A/G polymorphism of the serotonin 2A receptor gene. Neuropsychobiology. 2004;49:38-41.
44. Ni X, Trakalo JM, Mundo E, Lee L, Parikh S, Kennedy JL. Family-based association study of the serotonin-2A receptor gene (5-HT2A) and bipolar disorder. Neuromolecular Med. 2002;2:251-9.
45. Oswald P, Souery D, Massat I, Del-Favero J, Linotte S, Papadimitriou G, et al. Lack of association between the 5HT2A receptor polymorphism (T102C) and unipolar affective disorder in a multicentric European study. Eur Neuropsychopharmacol. 2003;13:365-8.
46. Stanley M, Virgilio J, Gershon S. Tritiated imipramine binding sites are decreased in the frontal cortex of suicides. Science. 1982;216:1337-9.
47. Mann JJ, McBride PA, Anderson GM, Mieczkowski TA. Platelet and whole blood serotonin content in depressed inpatients: correlations with acute and life-time psychopathology. Biol Psychiatry. 1992;32:243-57.
48. Audenaert K, Van Laere K, Dumont F, Slegers G, Mertens J, van Heeringen C, et al. Decreased frontal serotonin 5-HT 2a receptor binding index in deliberate self-harm patients. Eur J Nucl Med. 2001;28:175-82.
49. Stanley M, Mann JJ. Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet. 1983;1: 214-6.
50. Mann JJ, Stanley M, McBride PA, McEwen BS. Increased serotonin2 and beta-adrenergic receptor binding in the frontal cortices of suicide victims. Arch Gen Psychiatry. 1986;43:954-9.
51. Arango V, Ernsberger P, Marzuk PM, Chen JS, Tierney H, Stanley M, et al. Autoradiographic demonstration of increased serotonin 5-HT2 and beta-adrenergic receptor binding sites in the brain of suicide victims. Arch Gen Psychiatry. 1990;47:1038-47.
52. Hrdina PD, Demeter E, Vu TB, Sotonyi P, Palkovits M. 5-HT uptake sites and 5-HT2 receptors in brain of antidepressant-free suicide victims/depressives: increase in 5-HT2 sites in cortex and amygdala. Brain Res. 1993;614:37-44.
53. Hrdina PD, DU L. Levels of Serotonin Receptor 2A Higher in Suicide Victims? Am J Psychiatry. 2001; 158:146-7.
54. Pandey GN, Dwivedi Y, Rizavi HS, Ren X, Pandey SC, Pesold C, et al. Higher expression of serotonin 5-HT(2A) receptors in the postmortem brains of teenage suicide victims. Am J Psychiatry. 2002;159:419-29.
55. Escriba PV, Ozaita A, Garcia-Sevilla JA. Increased mRNA expression of alpha2A-adrenoceptors, serotonin receptors and mu-opioid receptors in the brains of suicide victims. Neuropsychopharmacology. 2004;29:1512-21.
56. Asberg M, Traskman L, Thoren P. 5-HIAA in the cerebrospinal fluid. A biochemical suicide predictor? Arch Gen Psychiatry. 1976;33:1193-7.
57. Du L, Bakish D, Lapierre YD, Ravindran AV, Hrdina PD. Association of polymorphism of serotonin 2A receptor gene with suicidal ideation in major depressive disorder. Am J Med Genet. 2000;96:56-60.
58. Peroutka SJ, Snyder SH. Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Science. 1980;210:88-90.
59. Preuss UW, Koller G, Bahlmann M, Soyka M, Bondy B. No association between suicidal behavior and 5-HT2A-T102C polymorphism in alcohol dependents. Am J Med Genet. 2000;96:877-8.
60. Bondy B, Kuznik J, Baghai T, Schule C, Zwanzger P, Minov C, et al. Lack of association of serotonin-2A receptor gene polymorphism (T102C) with suicidal ideation and suicide. Am J Med Genet. 2000;96:831-5.
61. Crawford J, Sutherland GR, Goldney RD. No evidence for association of 5-HT2A receptor polymorphism with suicide. Am J Med Genet. 2000;96:879-80.
62. Anguelova M, Benkelfat C, Turecki G. A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: II. Suicidal behavior. Mol Psychiatry. 2003;8:646-53.
63. Turecki GB, Dewar K, Lesage A, Seguin M, Chawky N, Vanier C, et al. Serotonin 2A Receptor Polymorphisms and [3H]Ketanserin Binding. Am J Psychiatry. 2000;157:1710.
64. Barbarich NC, Kaye WH, Jimerson D. Neurotransmitter and imaging studies in anorexia nervosa: new targets for treatment. Curr Drug Targets CNS Neurol Disord. 2003;2:61-72.
65. Ramacciotti CE, Coli E, Paoli R, Marazziti D, Dell'Osso L. Serotonergic activity measured by platelet [3H]paroxetirie binding in patients with eating disorders. Psychiatry Res. 2003;118:33-8.
66. Frank GK, Kaye WH, Meltzer CC, Price JC, Greer P, McConaha C, et al. Reduced 5-HT2A receptor binding after recovery from anorexia nervosa. Biol Psychiatry. 2002;52:896-906.
67. Audenaert K, Van Laere K, Dumont F, Vervaet M, Goethals I, Slegers G, et al. Decreased 5-HT2a receptor binding in patients with anorexia nervosa. J Nucl Med. 2003;44:163-9.
68. Bailer UF, Price JC, Meltzer CC, Mathis CA, Frank GK, Weissfeld L, et al. Altered 5-HT(2A) receptor binding after recovery from bulimia-type anorexia nervosa: relationships to harm avoidance and drive for thinness. Neuropsychopharmacology. 2004;29:1143-55.
69. Fink G, Sumner BE. Oestrogen and mental state. Nature. 1996;383:306.
70. Collier DA, Arranz MJ, Li T, Mupita D, Brown N, Treasure J. Association between 5-HT2A gene promoter polymorphism and anorexia nervosa. Lancet. 1997;350:412.
71. Hinney A, Ziegler A, Nothen MM, Remschmidt H, Hebebrand J. 5-HT2A receptor gene polymorphisms, anorexia nervosa, and obesity. Lancet. 1997;350:1324-5.
72. Campbell DA, Sundaramurthy D, Markham AF, Pieri LF. Lack of association between 5-HT2A gene promoter polymorphism and susceptibility to anorexia nervosa. Lancet. 1998;351:499.
73. Ziegler A, Hebebrand J, Gorg T, Rosenkranz K, Fichter M, Herpertz-Dahlmann B, et al. Further lack of association between the 5-HT2A gene promoter polymorphism and susceptibility to eating disorders and a meta-analysis pertaining to anorexia nervosa. Mol Psychiatry. 1999;4: 410-2.
74. Nacmias B, Ricca V, Tedde A, Mezzani B, Rotella CM, Sorbi S. 5-HT2A receptor gene polymorphisms in anorexia nervosa and bulimia nervosa. Neurosci Lett. 1999;277: 134-6.
75. Gorwood P, Ades J, Bellodi L, Cellini E, Collier DA, Di Bella D, et al. The 5-HT(2A) -1438G/A polymorphism in anorexia nervosa: a combined analysis of 316 trios from six European centres. Mol Psychiatry. 2002;7:90-4.
76. Sorbi S, Nacmias B, Tedde A, Ricca V, Mezzani B, Rotella CM. 5-HT2A promoter polymorphism in anorexia nervosa. Lancet. 1998;351:1785.
77. Enoch MA, Kaye WH, Rotondo A, Greenberg BD, Murphy DL, Goldman D. 5-HT2A promoter polymorphism -1438G/A, anorexia nervosa, and obsessive-compulsive disorder. Lancet. 1998;351:1785-6.
78. Kipman A, Bruins-Slot L, Boni C, Hanoun N, Ades J, Blot P, et al. 5-HT(2A) gene promoter polymorphism as a modifying rather than a vulnerability factor in anorexia nervosa. Eur Psychiatry. 2002;17:227-9.
79. Ricca V, Nacmias B, Cellini E, Di Bernardo M, Rotella CM, Sorbi S. 5-HT2A receptor gene polymorphism and eating disorders. Neurosci Lett. 2002;323:105-8.
80. Bell CJ, Nutt DJ. Serotonin and panic. Br J Psychiatry. 1998;172:465-71.
81. Nicolini H, Cruz C, Camarena B, Orozco B, Kennedy JL, King N, et al. DRD2, DRD3 and 5HT2A receptor genes polymorphisms in obsessive-compulsive disorder. Mol Psychiatry. 1996;1:461-5.
82. Frisch A, Michaelovsky E, Rockah R, Amir I, Hermesh H, Laor N, et al. Association between obsessive-compulsive disorder and polymorphisms of genes encoding components of the serotonergic and dopaminergic pathways. Eur Neuropsychopharmacol. 2000;10:205-9.
83. Tot S, Erdal ME, Yazici K, Yazici AE, Metin O. T102C and -1438 G/A polymorphisms of the 5-HT2A receptor gene in Turkish patients with obsessive-compulsive disorder. Eur Psychiatry. 2003;18:249-54.
84. Hemmings SM, Kinnear CJ, Niehaus DJ, Moolman-Smook JC, Lochner C, Knowles JA, et al. Investigating the role of dopaminergic and serotonergic candidate genes in obsessive-compulsive disorder. Eur Neuropsychopharmacol. 2003;13:93-8.
85. Meira-Lima I, Shavitt RG, Miguita K, Ikenaga E, Miguel EC, Vallada H. Association analysis of the catechol-o-methyltransferase (COMT), serotonin transporter (5-HTT) and serotonin 2A receptor (5HT2A) gene polymorphisms with obsessive-compulsive disorder. Genes Brain Behav. 2004;3:75-9.
86. Walitza S, Wewetzer C, Warnke A, Gerlach M, Geller F, Gerber G, et al. 5-HT2A promoter polymorphism -1438G/ A in children and adolescents with obsessive-compulsive disorders. Mol Psychiatry. 2002;7:1054-7.
87. Enoch MA, Greenberg BD, Murphy DL, Goldman D. Sexually dimorphic relationship of a 5-HT2A promoter polymorphism with obsessive-compulsive disorder. Biol Psychiatry. 2001;49:385-8.
88. Bellodi L, Cavallini MC, Bertelli S, Chiapparino D, Riboldi C, Smeraldi E. Morbidity risk for obsessive-compulsive spectrum disorders in first-degree relatives of patients with eating disorders. Am J Psychiatry. 2001;158:563-9.
89. Coleman M. Serotonin concentrations in whole blood of hyperactive children. J Pediatr. 1971;78:985-90.
90. Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science. 1999;283:397-401.
91. Quist JF, Barr CL, Schachar R, Roberts W, Malone M, Tannock R, et al. Evidence for the serotonin HTR2A receptor gene as a susceptibility factor in attention deficit hyperactivity disorder (ADHD). Mol Psychiatry. 2000; 5:537-41.
92. Levitan RD, Masellis M, Basile VS, Lam RW, Jain U, Kaplan AS, et al. Polymorphism of the serotonin-2A receptor gene (HTR2A) associated with childhood attention deficit hyperactivity disorder (ADHD) in adult women with seasonal affective disorder. J Affect Disord. 2002;71:229-33.
93. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease. II: Disorders of perception. Br J Psychiatry. 1990;157:76-81, 92-4.
94. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease. I: Disorders of thought content. Br J Psychiatry. 1990;157:72-6, 92-4.
95. Holmes C, Arranz MJ, Powell JF, Collier DA, Lovestone S. 5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease. Hum Mol Genet. 1998;7:1507-9.
96. Nacmias B, Tedde A, Forleo P, Piacentini S, Guarnieri BM, Bartoli A, et al. Association between 5-HT(2A) receptor polymorphism and psychotic symptoms in Alzheimer's disease. Biol Psychiatry. 2001;50:472-5.
97. Rocchi A, Micheli D, Ceravolo R, Manca ML, Tognoni G, Siciliano G, et al. Serotoninergic polymorphisms (5-HTTLPR and 5-HT2A): association studies with psychosis in Alzheimer disease. Genet Test. 2003;7:309-14.
98. Holmes C, Arranz M, Collier D, Powell J, Lovestone S. Depression in Alzheimer's disease: the effect of serotonin receptor gene variation. Am J Med Genet. 2003;119B:40-3.
99. Assal F, Alarcon M, Solomon EC, Masterman D, Geschwind DH, Cummings JL. Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease. Arch Neurol. 2004;61:1249-53.
100. Lam LC, Tang NL, Ma SL, Zhang W, Chiu HF. 5-HT2A T102C receptor polymorphism and neuropsychiatric symptoms in Alzheimer's disease. Int J Geriatr Psychiatry. 2004;19:523-6.
101. Marek GJ, Wright RA, Schoepp DD, Monn JA, Aghajanian GK. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. J Pharmacol Exp Ther. 2000;292:76-87.
102. Jedema HP, Moghaddam B. Glutamatergic control of dopamine release during stress in the rat prefrontal cortex. J Neurochem. 1994;63:785-8.
103. Takahata R, Moghaddam B. Glutamatergic regulation of basal and stimulus-activated dopamine release in the prefrontal cortex. J Neurochem. 1998;71:1443-9.